MRK

Moderna has surged over 600% in 2026, driven by breakthrough Phase 3 trial results for its personalized cancer vaccine (intismeran autogene) combined with Merck's Keytruda, plus FDA approval for its flu vaccine mFLUSIVA. However, despite strong innovation, the stock appears overvalued at a $90 billion market cap with a 45% downside according to Wall Street analysts. The company would need to generate unrealistic revenue levels to justify current valuations, leaving little room for error.

Moderna is transitioning from a COVID-19 vaccine company to an oncology-focused biotech firm. The company announced positive phase 3 results for its personalized cancer vaccine (intismeran autogene) paired with Merck's Keytruda for melanoma treatment. With the global oncology market projected to grow from $253 billion to over $700 billion by 2034, Moderna's stock has surged over 600% this year, though it now trades 61% above Wall Street's average price target of $123.

Merck (MRK) closed at $143.63, down 1.59% from the previous session, underperforming the S&P 500's 0.41% gain. The pharmaceutical company faces declining earnings expectations with Q3 EPS projected at $2.12 (down 17.83% YoY) and annual EPS forecast at $2.66 (down 70.38% YoY).

With a Zacks Rank of #4 (Sell), a Forward P/E of 54.92 significantly above the industry average of 16.91, and a PEG ratio of 6.74 versus the industry average of 2.01, Merck appears overvalued. Consensus EPS estimates have fallen 3.83% over the past month.